Seeking Alpha

AstraZeneca's (AZN) blockbuster cholesterol drug Crestor failed to beat Pfizer's (PFE) Lipitor...

AstraZeneca's (AZN) blockbuster cholesterol drug Crestor failed to beat Pfizer's (PFE) Lipitor in a head-to-head study. The result is likely to cap any benefits AZN might have gained from when Lipitor loses its patent in November and cheap generics hit the market. Shares -3.3% in London. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs